263 related articles for article (PubMed ID: 15138566)
1. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.
Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T
Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566
[TBL] [Abstract][Full Text] [Related]
2. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
Yeh S; Lin HK; Kang HY; Thin TH; Lin MF; Chang C
Proc Natl Acad Sci U S A; 1999 May; 96(10):5458-63. PubMed ID: 10318905
[TBL] [Abstract][Full Text] [Related]
3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
4. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
Gregory CW; Whang YE; McCall W; Fei X; Liu Y; Ponguta LA; French FS; Wilson EM; Earp HS
Clin Cancer Res; 2005 Mar; 11(5):1704-12. PubMed ID: 15755991
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
6. Signaling mechanisms that mediate invasion in prostate cancer cells.
Bonaccorsi L; Marchiani S; Muratori M; Carloni V; Forti G; Baldi E
Ann N Y Acad Sci; 2004 Dec; 1028():283-8. PubMed ID: 15650253
[TBL] [Abstract][Full Text] [Related]
7. The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells.
Hsu FN; Yang MS; Lin E; Tseng CF; Lin H
Am J Physiol Endocrinol Metab; 2011 May; 300(5):E902-8. PubMed ID: 21364123
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
9. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
10. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
Mahajan NP; Liu Y; Majumder S; Warren MR; Parker CE; Mohler JL; Earp HS; Whang YE
Proc Natl Acad Sci U S A; 2007 May; 104(20):8438-43. PubMed ID: 17494760
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.
Mellinghoff IK; Vivanco I; Kwon A; Tran C; Wongvipat J; Sawyers CL
Cancer Cell; 2004 Nov; 6(5):517-27. PubMed ID: 15542435
[TBL] [Abstract][Full Text] [Related]
12. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.
Craft N; Shostak Y; Carey M; Sawyers CL
Nat Med; 1999 Mar; 5(3):280-5. PubMed ID: 10086382
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
14. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Oncogene; 2004 Jul; 23(30):5175-84. PubMed ID: 15156193
[TBL] [Abstract][Full Text] [Related]
16. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
18. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
[TBL] [Abstract][Full Text] [Related]
19. Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo Z; Dai B; Jiang T; Xu K; Xie Y; Kim O; Nesheiwat I; Kong X; Melamed J; Handratta VD; Njar VC; Brodie AM; Yu LR; Veenstra TD; Chen H; Qiu Y
Cancer Cell; 2006 Oct; 10(4):309-19. PubMed ID: 17045208
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE
Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
